Andrea Messori

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 35

Top Topics

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Breast Reconstruction

Top Venues

Hematology reports

European journal of hospital pharmacy : science and practice

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, Andrea Messori, Vera Damuzzo
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. Cancers 16 (3) (2024)
Andrea Ossato, Lorenzo Gasperoni, Luna Del Bono, Andrea Messori, Vera Damuzzo
Efficacy of Immune Checkpoint Inhibitors vs. Tyrosine Kinase Inhibitors/Everolimus in Adjuvant Renal Cell Carcinoma: Indirect Comparison of Disease-Free Survival. Cancers 16 (3) (2024)
Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Emilio Francesco Giunta, Andrea Messori, Vera Damuzzo
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy? Cancers 16 (13) (2024)
Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Emilio Francesco Giunta, Andrea Messori, Vera Damuzzo
A Head-to-Head Comparison of the First-Line Treatments for Locally Advanced or Metastatic Urothelial Cancer: Is There Still a Role for Chemotherapy? Cancers 16 (13) (2024)
Andrea Messori, Sabrina Trippoli
Study of CardioMEMS in heart failure patients: Study confirms benefit in costs and quality-adjusted life years, but does not measure quality-adjusted life years. ESC heart failure (2024)
Melania Rivano, Daniele Mengato, Marco Chiumente, Andrea Messori
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons. Hematology reports 15 (4) (2023)
Andrea Messori, Giulia Hyeraci
Meta-analysis on allogeneic transplant for treating pediatric patients with acute myeloid leukemia in first remission: reanalysis of primary data. Annals of hematology (2023)
Luca Cancanelli, Melania Rivano, Lorenzo Di Spazio, Marco Chiumente, Daniele Mengato, Andrea Messori
Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematology reports 15 (1) (2023)
Andrea Messori, Vera Damuzzo, Melania Rivano, Luca Cancanelli, Lorenzo Di Spazio, Andrea Ossato, Marco Chiumente, Daniele Mengato
Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses. Cancers 15 (6) (2023)
Sabrina Trippoli, Valeria Fadda, Andrea Messori
In-hospital expenditure for medical devices: basic benchmarks for interpreting local data. European journal of hospital pharmacy : science and practice (2023)
Andrea Ossato, Daniele Mengato, Marco Chiumente, Andrea Messori, Vera Damuzzo
Progression-Free and Overall Survival of First-Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens. Cancers 15 (7) (2023)
Melania Rivano, Daniele Mengato, Marco Chiumente, Andrea Messori
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons. Hematology reports 15 (4) (2023)
Luca Cancanelli, Melania Rivano, Lorenzo Di Spazio, Marco Chiumente, Daniele Mengato, Andrea Messori
Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematology reports 15 (1) (2023)
Luca Cancanelli, Melania Rivano, Lorenzo Di Spazio, Marco Chiumente, Daniele Mengato, Andrea Messori
Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. Hematology reports 15 (1) (2023)
Andrea Messori, Vera Damuzzo, Melania Rivano, Luca Cancanelli, Lorenzo Di Spazio, Andrea Ossato, Marco Chiumente, Daniele Mengato
Application of the IPDfromKM-Shiny Method to Compare the Efficacy of Novel Treatments Aimed at the Same Disease Condition: A Report of 14 Analyses. Cancers 15 (6) (2023)
Melania Rivano, Daniele Mengato, Marco Chiumente, Andrea Messori
Low-Intensity and Chemo-Free Treatments in Ph+ ALL: Progression-Free Survival Based on Indirect Comparisons. Hematology reports 15 (4) (2023)
Andrea Messori, Sabrina Trippoli, Claudio Marinai
In-hospital expenditure for medical devices in relation to funds from diagnosis-related groups and ambulatory activity: temporal trend from 2019 to 2022. European journal of hospital pharmacy : science and practice (2023)
Daniele Mengato, Luca Cancanelli, Melania Rivano, Marco Chiumente, Lorenzo Di Spazio, Andrea Messori
First-line chemoimmunotherapy versus chemotherapy in PD-L1-negative patients with non-small-cell lung cancer. Immunotherapy 14 (11) (2022)
Andrea Messori, Sabrina Trippoli
Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials. Journal of chemotherapy (Florence, Italy) (2022)
Melania Rivano, Luca Cancanelli, Lorenzo Di Spazio, Daniele Mengato, Marco Chiumente, Andrea Messori
Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer: indirect comparison of three randomized phase-III trials. World journal of urology 40 (11) (2022)
Andrea Ossato, Vera Damuzzo, Paolo Baldo, Daniele Mengato, Marco Chiumente, Andrea Messori
Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data. Cancer medicine (2022)
Andrea Messori, Sabrina Trippoli, Laura Bartoli, Claudio Marinai
Defining innovativeness of high-technology medical devices in an Italian region. European journal of hospital pharmacy : science and practice (2022)
Andrea Messori, Manuela Angileri, Marco Chiumente, Laura Agnoletto, Paolo Baldo, Laura Bartoli, Mario Cirino, Vera Damuzzo, Elisa Ferracane, M Cecilia Giron, Carolina Laudisio, Daniele Mengato, Angelo Claudio Palozzo, Sabrina Trippoli
SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces. European journal of hospital pharmacy : science and practice (2021)
Andrea Messori, Melania Rivano, Daniele Mengato, Luca Cancanelli, Lorenzo Di Spazio, Marco Chiumente
A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia. Leukemia & lymphoma 63 (5) (2021)
Andrea Messori, Laura Bartoli, Elisa Ferracane, Sabrina Trippoli
"Real-world" endovascular versus surgical arteriovenous fistula economic evaluation: Can clinical outcomes and use of resources be derived from different countries? The journal of vascular access (2021)
Andrea Messori, Laura Bartoli, Sabrina Trippoli
The restricted mean survival time as a replacement for the hazard ratio and the number needed to treat in long-term studies. ESC heart failure 8 (3) (2021)
Melania Rivano, Luca Cancanelli, Lorenzo Di Spazio, Marco Chiumente, Daniele Mengato, Andrea Messori
Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies. Immunotherapy 13 (2) (2020)
Andrea Messori
CAR-T treatment: Determining the progression-free survival gain in patients with heavily pretreated multiple myeloma. EJHaem 1 (1) (2020)
Andrea Messori, Sabrina Trippoli, Erminia Caccese, Claudio Marinai
Tenders for the Procurement of Medical Devices: Adapting Cost-Effectiveness Rules to the Requirements of the European Public Procurement Directive. Therapeutic innovation & regulatory science 54 (1) (2020)
Andrea Messori, Laura Bartoli
Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line. Leukemia & lymphoma 62 (4) (2020)
Andrea Messori, Sabrina Trippoli, Claudio Marinai
The role of medical devices in influencing in-hospital sustainability: an analysis of expenditure in 2019 vs DRG reimbursement according to major medical specialties in a region of middle Italy. Expert review of medical devices 17 (10) (2020)
Andrea Messori, Laura Bartoli, Marco Chiumente, Daniele Mengato, Sabrina Trippoli
The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors. American journal of cardiovascular drugs : drugs, devices, and other interventions 21 (3) (2020)
Andrea Messori, Laura Bartoli, Daniele Mengato, Marco Chiumente
Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available. European journal of hospital pharmacy : science and practice (2020)
Andrea Messori, Laura Bartoli, Elisa Ferracane
Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis. Breast cancer research and treatment 185 (3) (2020)
Andrea Messori, Sabrina Trippoli
Incremental Cost-Effectiveness Ratio and Net Monetary Benefit: Promoting the Application of Value-Based Pricing to Medical Devices-A European Perspective. Therapeutic innovation & regulatory science 52 (6) (2018)